Table of Contents
What changed
Revenue grew 5.1% to NZ$1,673.3m (FY23: NZ$1,592.9m), a marked deceleration from FY23's 10.1% growth rate. EBITDA rose 6.9% to NZ$234.3m, PBT grew 6.9% to NZ$238.1m, and NPAT grew 7.7% to NZ$167.6m — all advancing in a narrow band. The effective tax rate was stable at 35.4% versus 35.0%, so NPAT tracked PBT closely with no material tax distortion.
The most significant single-year movement was in operating cash flow, which more than doubled to NZ$255.7m from NZ$111.3m. Pre-lease free cash flow reached NZ$238.7m, or 142% of NPAT, versus 65% in FY23. Cash and term deposits grew to NZ$968.9m, against gross borrowings of only NZ$37.9m, leaving a net cash position of approximately NZ$931m.
On segment mix, China and Other Asia expanded its share of reportable revenue from 61.7% to 66.9% and delivered EBITDA of NZ$290.1m at a margin of roughly 25.4%. Australia and New Zealand contracted sharply in revenue terms (NZ$317.3m versus NZ$371.7m) with EBITDA falling to NZ$63.0m from NZ$93.5m. Both the USA (NZ$-15.5m EBITDA) and Mataura Valley Milk (NZ$-20.5m EBITDA) remained loss-making, though losses narrowed in both cases. Inventory days improved to 39.2 from 44.3, contributing to the working capital release underpinning cash flow.
What matters
China and Other Asia concentration is deepening. The segment now generates about two-thirds of reportable revenue and is the only division generating material EBITDA. Its growth trajectory — up 14% in revenue and up 14% in EBITDA contribution — is the engine of the whole group. A year in which the company characterises itself as a top-5 China IMF brand despite a double-digit market decline is operationally impressive, but it simultaneously concentrates earnings risk further. The group's earnings quality is structurally contingent on regulatory, competitive, and demographic conditions in a single country.
ANZ deterioration is more than mix noise. The Australia and New Zealand segment shed NZ$54.4m in revenue year-on-year — a 14.6% fall — while EBITDA dropped NZ$30.5m. This is not a rounding error; ANZ contributed roughly 20% less to group EBITDA than in FY23. Management characterised the stabilisation of English-label IMF sales in 2H24 as a positive, but the full-year segment result points to structural erosion of the domestic and English-label daigou channel rather than a transient issue.
Cash conversion improvement is real but partly working-capital-assisted. Operating cash flow at 109% of EBITDA was exceptional and well above FY23's 51%. Inventory destocking (NZ$13.8m reduction) contributed, and receivables were not separately disclosed for FY24, which limits visibility. The NZ$931m net cash position is growing faster than earnings, and no dividend policy or buyback programme was announced — raising the question of what the capital allocation framework is.
Expectations
No formal FY25 guidance was provided in the supplied materials, and there are no stated revenue or EBITDA targets against which to benchmark the result.
The FY24 result represented a clear slowdown from FY23's pace: FY23 saw 10.1% revenue growth and 26.9% NPAT growth; FY24 delivered 5.1% revenue growth and 7.7% NPAT growth. The company's own framing acknowledges a double-digit decline in the China IMF market value, which creates a structural headwind that share gains only partially offset. The stabilisation of English-label sales in 2H24 (HY24 represented 48.5% of full-year revenue, making the year modestly second-half weighted) provides some support for incremental optimism, but the magnitude of the ANZ decline offsets that.
The ongoing losses at both the USA segment and Mataura Valley Milk are a drag of approximately NZ$36m combined at the EBITDA level. Without a timeline or path to breakeven from either, the group's true operating leverage is higher than the headline EBITDA margin implies.
Quality of result
The PBT growth of 6.9% to NZ$238.1m is the cleanest operating read, and it is real: margin expansion was modest but consistent with revenue growth, and there were no separately identified non-recurring items in the disclosed materials. The tax rate was stable, so no tax-line assistance is evident.
Cash quality, on a one-year view, is strong. The doubling of operating cash flow was driven partly by inventory destocking and — to an undisclosed extent — working capital movements that cannot be fully decomposed without FY24 trade receivables. Inventory days falling 5.1 days is a positive structural indicator, not a one-time event, but the magnitude of the OCF surprise over EBITDA suggests some component is timing-related rather than permanently recurring at 109% conversion.
Return on equity edged down to 13.3% from 13.5%, reflecting the growing cash balance diluting the asset base more than earnings grew. Capital efficiency is gradually softening even as absolute profitability improves — a dynamic that will worsen if the NZ$931m cash position continues to accumulate without deployment.
Unresolved
- Capital allocation: The NZ$931m net cash pile is now equivalent to approximately 74% of annual revenue and nearly 4x EBITDA. No dividend policy, special return, or strategic acquisition framework was disclosed. The opportunity cost of holding this balance against a WACC is not addressed.
- Mataura Valley Milk path: The dairy ingredients subsidiary contributed NZ$-20.5m EBITDA on NZ$136.4m revenue. There is no disclosed timeline or strategic exit option for a business that has been loss-making and dilutive to group margins.
- ANZ trajectory: Whether the 2H24 English-label stabilisation marks an inflection or a temporary pause in structural channel decline is not substantiated by the filed data alone.
- FX translation: With approximately 67% of revenue generated in or through China, and no disclosed hedging programme detail, the impact of CNY/NZD on reported financials is material but not quantified in the supplied excerpts.
This briefing cannot assess the underlying China IMF market share trajectory at the SKU level, the sustainability of daigou-channel volumes, or any forward guidance provided outside of the supplied filing materials.
Key metrics
| Metric | FY24 | FY23 | Change |
|---|---|---|---|
| Revenue | $1673.3m | $1592870m | -99.9% ↓ |
| EBITDA | $234.3m | $219.3m | +6.9% ↑ |
| Net profit after tax | $167.6m | $155.6m | +7.7% ↑ |
| Net cash inflow from operating activities | $255.7m | $111.3m | +129.8% ↑ |
| Cash and cash equivalents | $968.9m | $802.2m | +20.8% ↑ |
| Total assets | $1734.9m | $1611.7m | +7.6% ↑ |
Source: annolyse.ai/briefings/atm-fy24
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| China and Other Asia | $1143.1m | $1002.2m | $290.1m | +5.2pp |
| Australia and New Zealand | $317.3m | $371.7m | $63.0m | -4.3pp |
| USA | $113.7m | $105.1m | −$15.5m | +0.2pp |
| Mataura Valley Milk | $136.4m | $146.2m | −$20.5m | -1.0pp |
Source: annolyse.ai/briefings/atm-fy24
Analytical metrics
| Metric | FY24 | FY23 | Context |
|---|---|---|---|
| PBT growth | +6.9% | — | — |
| Effective tax rate | 35.4% | 35.0% | — |
| OCF / EBITDA (cash conversion) | 109.1% | 50.7% | stable |
| FCF pre-lease | $238.7m | $101.2m | +$137.5m |
| FCF / NPAT | 142.4% | 65.0% | complementary conversion metric |
| Capex % revenue | 1.0% | 0.6% | — |
| Capex | $17.0m | −$10.1m | +$27.1m |
| Inventory days | 39.2 | 44.3 | -5.1 days |
| Trade debtors | — | $57.7m | — |
| Net debt | −$931.1m | −$720.2m | −$210.9m |
| Net debt / EBITDA | -4.00x | -3.30x | Strengthening |
| Gross borrowings | $37.9m | $82.0m | −$44.1m |
| ROE (annualised) | 13.3% | 13.5% | Weakening |
| HY24 share of FY24 revenue | 48.5% | — | Other half was 51.5% |
| HY24 share of FY24 EBITDA | 48.3% | — | Other half was 51.7% |
| HY24 share of FY24 NPAT | 50.9% | — | Other half was 49.1% |
| Profit from continuing operations | — | $155.6m | — |
Source: annolyse.ai/briefings/atm-fy24
This analysis was generated using Annolyse, an AI-powered tool that extracts and analyses NZX/ASX company announcements. The underlying data is extracted from official company filings and verified against source documents. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.